Browse ELF4

Summary
SymbolELF4
NameE74-like factor 4 (ets domain transcription factor)
Aliases ELFR; myeloid Elf-1-like factor; E74-like factor 4; ETS-related transcription factor Elf-4
Chromosomal LocationXq26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus, PML body Note=Accumulation into PML nuclear bodies is mediated by PML.
Domain PF12310 Transcription factor protein N terminal
PF00178 Ets-domain
Function

Transcriptional activator that binds to DNA sequences containing the consensus 5'-WGGA-3'. Transactivates promoters of the hematopoietic growth factor genes CSF2, IL3, IL8, and of the bovine lysozyme gene. Acts synergistically with RUNX1 to transactivate the IL3 promoter (By similarity). Also transactivates the PRF1 promoter in natural killer (NK) cells. Plays a role in the development and function of NK and NK T-cells and in innate immunity. Controls the proliferation and homing of CD8+ T-cells via the Kruppel-like factors KLF4 and KLF2 (By similarity). Controls cell senescence in a p53-dependent manner. Can also promote cellular transformation through inhibition of the p16 pathway.

> Gene Ontology
 
Biological Process GO:0001787 natural killer cell proliferation
GO:0001866 NK T cell proliferation
GO:0007159 leukocyte cell-cell adhesion
GO:0030101 natural killer cell activation
GO:0032943 mononuclear cell proliferation
GO:0042098 T cell proliferation
GO:0042110 T cell activation
GO:0046631 alpha-beta T cell activation
GO:0046633 alpha-beta T cell proliferation
GO:0046651 lymphocyte proliferation
GO:0051132 NK T cell activation
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0070661 leukocyte proliferation
GO:0071593 lymphocyte aggregation
Molecular Function GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding
GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0000987 core promoter proximal region sequence-specific DNA binding
GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001159 core promoter proximal region DNA binding
GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding
Cellular Component GO:0005635 nuclear envelope
GO:0016604 nuclear body
GO:0016605 PML body
GO:0031965 nuclear membrane
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolELF4
NameE74-like factor 4 (ets domain transcription factor)
Aliases ELFR; myeloid Elf-1-like factor; E74-like factor 4; ETS-related transcription factor Elf-4
Chromosomal LocationXq26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ELF4 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolELF4
NameE74-like factor 4 (ets domain transcription factor)
Aliases ELFR; myeloid Elf-1-like factor; E74-like factor 4; ETS-related transcription factor Elf-4
Chromosomal LocationXq26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ELF4 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolELF4
NameE74-like factor 4 (ets domain transcription factor)
Aliases ELFR; myeloid Elf-1-like factor; E74-like factor 4; ETS-related transcription factor Elf-4
Chromosomal LocationXq26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ELF4 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.3510.299
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.3950.767
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.3080.717
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0880.823
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.1850.932
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4360.878
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.4150.32
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.5090.685
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.250.865
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.9310.403
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.0950.528
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.030.739
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ELF4 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.1011.10.0181
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.1011.10.0286
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)2117011.8-11.80.193
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86016.7-16.70.429
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolELF4
NameE74-like factor 4 (ets domain transcription factor)
Aliases ELFR; myeloid Elf-1-like factor; E74-like factor 4; ETS-related transcription factor Elf-4
Chromosomal LocationXq26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ELF4. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolELF4
NameE74-like factor 4 (ets domain transcription factor)
Aliases ELFR; myeloid Elf-1-like factor; E74-like factor 4; ETS-related transcription factor Elf-4
Chromosomal LocationXq26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ELF4. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ELF4.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolELF4
NameE74-like factor 4 (ets domain transcription factor)
Aliases ELFR; myeloid Elf-1-like factor; E74-like factor 4; ETS-related transcription factor Elf-4
Chromosomal LocationXq26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ELF4. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolELF4
NameE74-like factor 4 (ets domain transcription factor)
Aliases ELFR; myeloid Elf-1-like factor; E74-like factor 4; ETS-related transcription factor Elf-4
Chromosomal LocationXq26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ELF4 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolELF4
NameE74-like factor 4 (ets domain transcription factor)
Aliases ELFR; myeloid Elf-1-like factor; E74-like factor 4; ETS-related transcription factor Elf-4
Chromosomal LocationXq26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ELF4 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolELF4
NameE74-like factor 4 (ets domain transcription factor)
Aliases ELFR; myeloid Elf-1-like factor; E74-like factor 4; ETS-related transcription factor Elf-4
Chromosomal LocationXq26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ELF4 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.